Global Ophthalmology Drugs Market OutlookThe global ophthalmology drugs market is forecasted to expand at a CAGR of nearly 8% over the next several years, driven by the rising burden of vision ...

In diabetic macular edema, faricimab can improve visual acuity for treatment-naïve eyes or sustain vision for those ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Abstract: Diabetic Retinopathy (DR) is a condition that is marked by deterioration of retinal blood vessels due to diabetes, serving as a primary factor for vision impairment. Diabetic Macular Edema ...

Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

India’s soaring diabetes burden is fuelling a silent surge in diabetic retinopathy. Firstpost brings out a doctor’s ...

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system ...

Please provide your email address to receive an email when new articles are posted on . Lamivudine improved visual acuity in patients with center-involved diabetic macular edema. Researchers said the ...

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global ...

Detailed price information for Clearside Biomedical Inc (CLSD-Q) from The Globe and Mail including charting and trades.